The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

L.M. 't Hart; A. Fritsche; G. Nijpels; N. van Leeuwen; L.A. Donnelly; J.M. Dekker; M.J. Alssema; J. Fadista; F. Carlotti; A.P. Gjesing; C.N.A. Palmer; T.W. van Haeften; S.A. Herzberg-Schäfer; A.M.C. Bik-Simonis; J.J. Houwing-Duistermaat; Q. Helmer; J. Deelen; B. Guigas; T. Hansen; F. Machicao; G. Willemsen; R.J. Heine; M.H.H. Kramer; J.J. Holst; E.J.P. de Koning; H.U. Häring; O. Pedersen; L. Groop; E.J.C. de Geus; P.E. Slagboom; D.I. Boomsma; E.M.W. Eekhoff; E.R. Pearson; M. Diamant

doi:https://doi.org/10.2337/db13-0227

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

L.M. 't Hart, A. Fritsche, G. Nijpels, N. van Leeuwen, L.A. Donnelly, J.M. Dekker, M.J. Alssema, J. Fadista, F. Carlotti, A.P. Gjesing, C.N.A. Palmer, T.W. van Haeften, S.A. Herzberg-Schäfer, A.M.C. Bik-Simonis, J.J. Houwing-Duistermaat, Q. Helmer, J. Deelen, B. Guigas, T. Hansen, F. MachicaoG. Willemsen, R.J. Heine, M.H.H. Kramer, J.J. Holst, E.J.P. de Koning, H.U. Häring, O. Pedersen, L. Groop, E.J.C. de Geus, P.E. Slagboom, D.I. Boomsma, E.M.W. Eekhoff, E.R. Pearson, M. Diamant

Research output: Contribution to journal › Article › Academic › peer-review

83 Citations (Scopus)

Abstract

The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances b-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (3040%) on GLP-1stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P ≤8.8 × 10

Original language	English
Pages (from-to)	3275-3281
Journal	Diabetes
Volume	62
Issue number	9
Early online date	14 May 2013
DOIs	https://doi.org/10.2337/db13-0227
Publication status	Published - 2013

Cohort Studies

Netherlands Twin Register (NTR)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.2337/db13-0227

Cite this

't Hart, L. M., Fritsche, A., Nijpels, G., van Leeuwen, N., Donnelly, L. A., Dekker, J. M., Alssema, M. J., Fadista, J., Carlotti, F., Gjesing, A. P., Palmer, C. N. A., van Haeften, T. W., Herzberg-Schäfer, S. A., Bik-Simonis, A. M. C., Houwing-Duistermaat, J. J., Helmer, Q., Deelen, J., Guigas, B., Hansen, T., ... Diamant, M. (2013). The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes, 62(9), 3275-3281. https://doi.org/10.2337/db13-0227

@article{d25404bf88a943e5afa118949d591d2c,

title = "The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway",

abstract = "The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances b-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (3040%) on GLP-1stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P ≤8.8 × 10",

author = "{'t Hart}, L.M. and A. Fritsche and G. Nijpels and {van Leeuwen}, N. and L.A. Donnelly and J.M. Dekker and M.J. Alssema and J. Fadista and F. Carlotti and A.P. Gjesing and C.N.A. Palmer and {van Haeften}, T.W. and S.A. Herzberg-Sch{\"a}fer and A.M.C. Bik-Simonis and J.J. Houwing-Duistermaat and Q. Helmer and J. Deelen and B. Guigas and T. Hansen and F. Machicao and G. Willemsen and R.J. Heine and M.H.H. Kramer and J.J. Holst and {de Koning}, E.J.P. and H.U. H{\"a}ring and O. Pedersen and L. Groop and {de Geus}, E.J.C. and P.E. Slagboom and D.I. Boomsma and E.M.W. Eekhoff and E.R. Pearson and M. Diamant",

year = "2013",

doi = "https://doi.org/10.2337/db13-0227",

language = "English",

volume = "62",

pages = "3275--3281",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association Inc.",

number = "9",

}

't Hart, LM, Fritsche, A, Nijpels, G, van Leeuwen, N, Donnelly, LA, Dekker, JM, Alssema, MJ, Fadista, J, Carlotti, F, Gjesing, AP, Palmer, CNA, van Haeften, TW, Herzberg-Schäfer, SA, Bik-Simonis, AMC, Houwing-Duistermaat, JJ, Helmer, Q, Deelen, J, Guigas, B, Hansen, T, Machicao, F, Willemsen, G, Heine, RJ, Kramer, MHH, Holst, JJ, de Koning, EJP, Häring, HU, Pedersen, O, Groop, L, de Geus, EJC, Slagboom, PE, Boomsma, DI, Eekhoff, EMW, Pearson, ER & Diamant, M 2013, 'The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway', Diabetes, vol. 62, no. 9, pp. 3275-3281. https://doi.org/10.2337/db13-0227

TY - JOUR

T1 - The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

AU - 't Hart, L.M.

AU - Fritsche, A.

AU - Nijpels, G.

AU - van Leeuwen, N.

AU - Donnelly, L.A.

AU - Dekker, J.M.

AU - Alssema, M.J.

AU - Fadista, J.

AU - Carlotti, F.

AU - Gjesing, A.P.

AU - Palmer, C.N.A.

AU - van Haeften, T.W.

AU - Herzberg-Schäfer, S.A.

AU - Bik-Simonis, A.M.C.

AU - Houwing-Duistermaat, J.J.

AU - Helmer, Q.

AU - Deelen, J.

AU - Guigas, B.

AU - Hansen, T.

AU - Machicao, F.

AU - Willemsen, G.

AU - Heine, R.J.

AU - Kramer, M.H.H.

AU - Holst, J.J.

AU - de Koning, E.J.P.

AU - Häring, H.U.

AU - Pedersen, O.

AU - Groop, L.

AU - de Geus, E.J.C.

AU - Slagboom, P.E.

AU - Boomsma, D.I.

AU - Eekhoff, E.M.W.

AU - Pearson, E.R.

AU - Diamant, M.

PY - 2013

Y1 - 2013

N2 - The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances b-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (3040%) on GLP-1stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P ≤8.8 × 10

AB - The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances b-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (3040%) on GLP-1stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P ≤8.8 × 10

U2 - https://doi.org/10.2337/db13-0227

DO - https://doi.org/10.2337/db13-0227

M3 - Article

C2 - 23674605

SN - 0012-1797

VL - 62

SP - 3275

EP - 3281

JO - Diabetes

JF - Diabetes

IS - 9

ER -